What is Regeneron Pharmaceuticals Operating Cash Flow per Share?
Regeneron Pharmaceuticals's operating cash flow per share for the
three
months ended in Dec. 2023 was $9.58.
Regeneron Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $40.38.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Regeneron Pharmaceuticals was -8.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 21.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 25.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Regeneron Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
REGN'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -80.3 Med: 21.1 Max: 64.1
Current: 21.1
During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.10% per year. The lowest was -80.30% per year. And the median was 21.10% per year.
REGN's 3-Year OCF Growth Rate is ranked better than 69.79% of 1238
companies
in the Biotechnology industry
Industry Median: 3.5
vs REGN: 21.10
Regeneron Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for Regeneron Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Regeneron Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of Regeneron Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Regeneron Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Regeneron Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 